NASDAQ:TCON - TRACON Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 117.65 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.27
▲ +0.05 (0.61%)
1 month | 3 months | 12 months
Get New TRACON Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCON

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.00
▲ +117.65% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for TRACON Pharmaceuticals in the last 3 months. The average price target is $18.00, with a high forecast of $24.00 and a low forecast of $12.00. The average price target represents a 117.65% upside from the last price of $8.27.
Buy
The current consensus among 2 polled investment analysts is to buy stock in TRACON Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/10/2021Maxim GroupInitiated CoverageBuy$24.00Low
i
12/4/2020HC WainwrightBoost Price TargetPositive ➝ Buy$7.00 ➝ $12.00High
i
Rating by Edward White at HC Wainwright
9/17/2020HC WainwrightBoost Price TargetBuy$4.00 ➝ $7.00High
i
Rating by Edward White at HC Wainwright
8/17/2020HC WainwrightReiterated RatingBuy$4.00High
i
Rating by Edward White at HC Wainwright
4/24/2020HC WainwrightLower Price TargetBuy$6.00 ➝ $4.00Medium
i
Rating by Edward White at HC Wainwright
3/10/2020HC WainwrightLower Price TargetBuy$13.00 ➝ $6.00High
i
Rating by Edward White at HC Wainwright
2/28/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $13.00High
i
Rating by Edward White at HC Wainwright
1/17/2020HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Edward White at HC Wainwright
12/23/2019HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00Medium
i
Rating by E. White at HC Wainwright
11/7/2019HC WainwrightReiterated RatingBuy$2.00High
i
Rating by E. White at HC Wainwright
8/29/2019HC WainwrightInitiated CoverageBuy$2.00High
i
Rating by E. White at HC Wainwright
4/12/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
Rating by Robert Hazlett at BTIG Research
3/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00High
i
12/26/2018BTIG ResearchLower Price TargetBuy$9.00Low
i
5/10/2018Needham & Company LLCLower Price TargetBuy$8.00High
i
6/13/2017Stifel NicolausLower Price TargetBuy ➝ Buy$14.00 ➝ $6.00High
i
1/5/2017Stifel NicolausReiterated RatingBuy$14.00N/A
i
1/3/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
12/21/2016Jefferies Financial GroupInitiated CoverageBuy$10.00N/A
i
10/5/2016Stifel NicolausReiterated RatingBuy$14.00N/A
i
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00N/A
i
(Data available from 3/8/2016 forward)
TRACON Pharmaceuticals logo
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $8.27
$8.16
$8.70

50 Day Range

MA: $10.07
$8.15
$11.65

52 Week Range

Now: $8.27
$0.95
$12.20

Volume

5,191 shs

Average Volume

574,205 shs

Market Capitalization

$128.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Frequently Asked Questions

What sell-side analysts currently cover shares of TRACON Pharmaceuticals?

The following equities research analysts have issued reports on TRACON Pharmaceuticals in the last twelve months: HC Wainwright, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for TCON.

What is the current price target for TRACON Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for TRACON Pharmaceuticals in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 117.7%. Maxim Group has the highest price target set, predicting TCON will reach $24.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for TRACON Pharmaceuticals in the next year.
View the latest price targets for TCON.

What is the current consensus analyst rating for TRACON Pharmaceuticals?

TRACON Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCON will outperform the market and that investors should add to their positions of TRACON Pharmaceuticals.
View the latest ratings for TCON.

What other companies compete with TRACON Pharmaceuticals?

How do I contact TRACON Pharmaceuticals' investor relations team?

TRACON Pharmaceuticals' physical mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company's listed phone number is 858-550-0780 and its investor relations email address is [email protected] The official website for TRACON Pharmaceuticals is www.traconpharma.com.